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Scheme S1. The derivatization reaction employing maltoheptaose as an example. Portions in the dotted rectangle are the 
terminal Glucose (reducing terminus) chemical structure undergoing reaction. 
 
 
Scheme S2. Synthesis of proton reagent for acid-catalyzed glycan sequencing (PRAGS). 
 
 
Scheme S3. Alternative mechanism for the formation of Y ions upon CID of singly-protonated PRAGS-derivatized 
maltoheptaose. 
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Scheme S4. Proposed mechanism for the formation of Y ions upon CID of GT-derivatized maltoheptaose. 
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Scheme S5. Proposed alternative mechanism for the formation of Z ions upon CID of singly-protonated FRAGS-
derivatized maltoheptaose. 
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Scheme S6. Proposed mechanism for the formation of 0,2X ions upon CID of singly-protonated FRAGS-derivatized 
maltoheptaose. 
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Scheme S7. Proposed mechanism for the formation of n ions upon CID of singly-protonated FRAGS-derivatized 
maltoheptaose. 
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Scheme S8. Proposed mechanism for the formation of –CH6O3 ions upon CID of singly-protonated FRAGS-derivatized 
nigerose. 
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Scheme S9. Proposed mechanism for the formation of Z1H+Z1L-H ion upon CID of singly-protonated FRAGS-derivatized 
LNDFH II. 
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Figure S1. MS1 spectrum of FRAGS-derivatized maltoheptaose. 
 
 
Figure S2. CID spectra for PRAGS- (top) and GT- (bottom) derivatized maltoheptaose. 
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Figure S3: CID of the singly-protonated FRAGS-derivatized lactose (top) and maltose (bottom). 
 
 
Figure S4. The fragmentation patterns observed following CID of Z3HH+Z3HL+H ion of LNDFH II (left), and the CID 
spectrum of Z3HH+Z3HL+H ion (right). 
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Procedure for purification of PRAGS and FRAGS derivatized glycans using C18 pipet tip 
1. Attach a C18 pipet tips to a micropipettor and condition twice by aspirating 10 µl of 1:1 
acetonitrile/water. 
2. Wash pipet tip twice with 10 µl water. 
3. Draw up 10 µl of aqueous glycan derivatization solution and return to the main solution. Repeat 
approximately ten times to saturate the C18 pipet tip with the derivatized glycan.  
4. Wash pipet tip twice with 10 µl water. 
5. Draw up 10 µl of 1:1 acetonitrile/water and return to the main solution. Repeat approximately ten 
times to elute glycans. 
The solution can be used directly for ESI-MS. 
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Lewis-Y tetrasaccharide. Lewis-Y tetrasaccharide was used as another model glycan, in which a 
centralized reducing terminus exists on the second sugar, yielding a branched site following 
derivatization, as shown in Figure S5. Similar to collisional activation of singly-protonated PRAGS-
derivatized maltohelpaose (Figure 2), collisional activation of singly-protonated PRAGS-derivatized 
Lewis-Y tetrasaccharide generates exclusively C1–O glycosidic bond cleavages retaining charge on the 
reducing terminus. However, the latter also generates ions with two C1–O glycosidic bond cleavages 
from each branch retaining charge on the reducing terminus (Y+Y ions, Figure S5). Two product ions, 
denoted Y1H (m/z 474.3, Figure S5) and Y1L+Y2H (m/z 490.3, Figure S5), can be employed to illustrate 
the site of reducing terminus as well as the branch structure information of PRAGS-derivatized Lewis-Y 
tetrasaccharide. The mass difference of Y1H and Y1L+Y2H is due to the mass difference between Fucose 
(164.2) and galactose (180.2). Therefore, CID of singly-protonated PRAGS-derivatized Lewis-Y 
tetrasaccharide provides information not only for composition and sequence analysis but also for the 
branch structure analysis. However, if the branched ions Y1H and Y1L+Y2H ions have the same m/z value, 
one cannot unambiguously identify the existence of a branched structure. In this case, the FRAGS 
reagent can be utilized to yield much more branching information as explained below.  
Unlike collisional activation of singly-protonated FRAGS-derivatized maltoheptaose, collisional 
activation of singly-protonated FRAGS-derivatized Lewis-Y tetrasaccharide generates not only a 
systematic series of 1,5X, 0,2X, Y and Z ions but also a systematic series of Y+1,5X ions and Y+Y ions 
(Figure S5). It needs to be pointed out that there are no n ions formed. The Y and Y+Y ions have been 
observed in the CID of singly-protonated PRAGS-derivatized Lewis-Y tetrasaccharide. Two product 
ions, denoted 1,5X2H+Y1L or 1,5X1L+Y2H (m/z 532.3, Figure S5), 1,5X1H+Y1L or 1,5X1L+Y1H (m/z 370.2, 
Figure S5), can be employed to illustrate the existence of the branch structure. Moreover, two more 
characteristic ions, Z1H+Z1L-H (m/z 306.2, Figure S5) and Z1H+Y1L or Z1L+Y1H (m/z 324.2, Figure S5), 
which are produced only at the branched site, provide additional evidence for the existence of the 
branch structure. Furthermore, Z1H+Z1L-H ion provides information for the site of reducing terminus. 
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FRAGS is capable of identifying branched sites in even more complicated glycans, as outlined in the 
analysis of the CID spectrum of FRAGS-derivatized Lacto-N-difucohexaose II (Figure 6).  
The formation of Z1H+Z1L-H ion is proposed to occur-via a radical driven mechanism (Scheme S7). 
Briefly, dissociation is proposed to occur via hydrogen atom abstraction by the nascent free radical from 
C2 of the central saccharide unit, followed by homolytic cleavage of the α-glycosidic bond to form a 
double bond between C2 and C3. The resulting oxygen-centered radical then abstracts a hydrogen atom 
from C5, followed by homolytic cleavage of the β-glycosidic bond to form a double bond between C4 
and C5. 
 
 
Figure S5. The the fragmentation patterns observed following CID of singly-protonated PRAGS-derivatized (a) and 
FRAGS-derivatized (c) Lewis-Y tetrasaccharide, and CID specta of singly-protonated PRAGS-derivatized (b) and FRAGS-
derivatized (d) Lewis-Y tetrasaccharide.  
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Synthesis of FRAGS and PRAGS reagents 
Methyl 5-(bromomethyl)nicotinate (4) 
 
To a solution of methyl 5-methylnicotinate (3) (1.51 g, 10 mmol) and N-bromosuccinimide (NBS) 
(2.13 g, 12 mmol) in CCl4 (50 mL) was added benzoyl peroxide (24.2 mg, 0.1 mmol) under argon.1 The 
reaction mixture was stirred under reflux for 10 h. After cooling to room temperature, the reaction 
mixture was extracted with CH2Cl2 (×3). The extract was washed with brine, dried over anhydrous 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography 
on silica gel (hexane–EtOAc 1 : 1) to give methyl 5-(bromomethyl)nicotinate (4) as a white solid (1.17 
g, 51%). 1HNMR (500 MHz, CDCl3, δ ppm): 9.13 (d, J = 2.0 Hz, 1H), 8.78 (d, J = 2.2 Hz, 1H), 8.32 (t, 
J = 2.2 Hz, 1H), 4.50 (s, 2H), 3.96 (s, 3H). ); 13C NMR (125 MHz, CDCl3, δ ppm), 28.6, 52.5, 126.0, 
133.6, 137.5, 150.4, 153.3, 165.1. ESI-MS: [M+H]+, 230.0, 232.0. 
 
Methyl 5-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)nicotinate (5) 
 
To a Schlenk flask was added 4 (1.15 g, 5mmol), (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO, 
936 mg, 6 mmol), Cu(OTf)2 (217 mg, 0.6 mmol), copper powder (32.0 mg, 5 mmol), 4,4’-dinonyl-2,2’-
bipyridyl (Nbpy, 818 mg, 2 mmol), and benzene (15 mL).1 The reaction mixture was degassed by 
bubbling argon for 5 min and heated at 80 ˚C overnight. After cooling the reaction mixture to room 
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temperature, it was filtered through a short pad of silica gel using EtOAc. The filtrate was concentrated 
in vacuo and the residue was purified by flash column chromatography using hexane–EtOAc (3 : 1). 
The desired product 5 was obtained as a white solid (1.16 g, 76%). 1HNMR (500 MHz, CDCl3, δ ppm): 
9.09 (d, J = 2.1 Hz, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.20 (m, 1H), 4.84 (s, 2H), 3.92 (s, 3H), 1.53 (m, 1H), 
1.45 (m, 4H), 1.30 (m, 1H), 1.19 (s, 6H),  1.10 (s, 6H); 13C NMR (125 MHz, CDCl3, δ ppm), 16.9, 20.1, 
32.7, 39.5, 52.3, 60.0, 75.7, 125.6, 133.4, 135.8, 149.7, 152.5, 165.7. ESI-MS: [M+H]+, 307.3. 
 
(5-(((2,2,6,6-Tetramethylpiperidin-1-yl)oxy)methyl)pyridin-3-yl)methanol (6) 
 
To a solution of 5 (1.07 g, 3.5 mmol) in anhydrous ethanol (20 mL) was added sodium borohydride 
(266 mg, 7 mmol) portionally under argon.2 The reaction mixture was stirred under reflux overnight. 
After cooling to room temperature, the reaction mixture was diluted by adding 50 ml EtOAc, washed by 
water and brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified 
by flash chromatography on silica gel (hexane–EtOAc 1 : 1 to 1 : 5) to give the desired product 6 as a 
white solid (731 mg, 75%). 1HNMR (500 MHz, CD3OD, δ ppm): 8.45 (d, J = 2.1 Hz, 1H), 8.43 (d, J = 
2.1 Hz, 1H), 7.83 (m, 1H), 4.89 (s, 2H), 4.68 (m, 2H), 1.66 (m, 1H), 1.54 (m, 4H), 1.38 (m, 1H), 1.26 (s, 
6H), 1.16 (s, 6H); 13C NMR (125 MHz, CD3OD, δ ppm), 18.2, 20.8, 33.7, 40.9, 61.4, 62.5, 77.3, 135.5, 
136.1, 139.1, 148.0. ESI-MS: [M+H]+, 279.3. 
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2-((5-(((2,2,6,6-Tetramethylpiperidin-1-yl)oxy)methyl)pyridin-3-yl)methoxy)isoindoline-1,3-
dione (8) 
 
To a solution of 6 (557 mg, 2 mmol), 2-hydroxyisoindoline-1,3-dione (7, 391mg, 2.4 mmol), and 
triphenylphosphine (629 mg, 2.4 mmol)  in anhydrous THF (20 mL) was added a solution of 
diisopropyl azodicarboxylate (DIAD, 525 mg, 2.6 mmol) in 5 ml anhydrous THF at 0 ˚C under argon.3 
The reaction mixture was stirred at 0 ˚C for 30 minutes and then warmed to room temperature and 
stirred overnight. The reaction mixture was washed by water and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (hexane–
EtOAc 1 : 2) to give the desired product 8 as a white solid (695 mg, 82%). 1HNMR (500 MHz, CDCl3, δ 
ppm): 8.60 (d, J = 2.1 Hz, 1H), 8.58 (d, J = 2.0 Hz, 1H), 7.86 (t, J = 2.1 Hz, 1H), 7.78 (dd, J1 = 2.1 Hz, 
J2 = 5.5 Hz, 2H), 7.71 (dd, J1 = 2.1 Hz, J2 = 5.5 Hz, 2H), 5.22 (s, 2H), 4.83 (s, 2H), 1.55 (m, 1H), 1.45 
(m, 4H), 1.32 (m, 1H), 1.26 (s, 6H), 1.15 (s, 6H); 13C NMR (125 MHz, CDCl3, δ ppm), 16.9, 20.1, 32.9, 
39.5, 60.0, 75.8, 77.0, 123.5, 128.6, 128.9, 133.5, 134.5, 136.3, 149.5, 149.7, 163.2. ESI-MS: [M+H]+, 
424.4. 
 
O-((5-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyridin-3-yl)methyl)hydroxylamine 
(FRAGS, 2) 
 
To a solution of 8 (1.07 g, 1.5 mmol) in anhydrous ethanol (20 mL) was added hydrazine hydrate 
(N2H4, 50-60%, 0.86 mL, 15 mmol) portionally under argon.3 The reaction mixture was stirred under 
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reflux overnight. After cooling to room temperature, the reaction mixture was concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel (CHCl3–Hexane 3 : 1) to give the 
desired product 2 as a white solid (378 mg, 86%). 1HNMR (500 MHz, CDCl3, δ ppm): 8.57 (s, 1H), 
8.54 (s, 1H), 7.67 (t, J = 2.1 Hz, 1H), 4.86 (s, 2H), 4.72 (s, 2H), 1.59 (m, 1H), 1.50 (m, 4H), 1.37 (m, 
1H), 1.26 (s, 6H), 1.15 (s, 6H); 13C NMR (125 MHz, CDCl3, δ ppm), 17.0, 20.3, 33.0, 39.6, 60.1, 75.2, 
76.2, 132.6, 133.4, 135.3, 148.5, 148.8. ESI-MS: [M+H]+, 294.4. 
O-(pyridin-3-ylmethyl)hydroxylamine (PRAGS, 1) 
 
O-(pyridin-3-ylmethyl)hydroxylamine (PRAGS, 1) was synthesized following the procedure for 
synthesis of FRAGS reagent (2).3 Overall yield 46%.  1HNMR (500 MHz, CD3OD, δ ppm): 8.54 (d, 1H), 
8.47 (dd, J1 = 1.6 Hz, J2 = 5.0 Hz, 1H), 7.85 (m, 1H), 7.44 (m, 1H), 4.71 (s, 2H); 13C NMR (125 MHz, 
CDCl3, δ ppm), 75.4, 125.3, 135.7, 138.4, 149.5, 150.1. ESI-MS: [M+H]+, 125.1. 
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